primary biliary cirrhosis: Primary biliary cholangitis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
123 |
4. Check minimum number of eventsNone |
123 |
5. Include endpointsNone |
123 |
6. Filter based on genotype QC (FinnGen only) |
105 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- K74
- Name in latin
- Cirrhosis biliaris non specificata
Similar endpoints
↥List of similar endpoints to
Biliary cirrhosis, NAS
based on the number of shared cases.
Similar with more cases:
- Fibrosis and cirrhosis of liver
- Diseases of liver
- Gastrointestinal diseases
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 740 | 440 | 291 |
| Only index persons | 591 | 365 | 226 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 66.30 | 67.90 | 64.08 |
| Only index persons | 65.48 | 66.47 | 63.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 105 | 69 | 36 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 65.28 | 64.72 | 66.36 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 111
- Matched controls
- 1110
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
K74.5
ICD-10 Finland
Biliary cirrhosis, unspecified
+∞
160.1
111
*
A05AA02
ATC
ursodeoxycholic acid; oral
240.8
78.9
74
9
K74.3
ICD-10 Finland
Primary biliary cirrhosis
416.5
64.6
59
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
17.3
53.4
64
81
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
82.3
41.5
45
9
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
10.3
29.5
42
62
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
45.6
29.0
35
11
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.9
24.1
44
85
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
50.3
20.5
24
6
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
6.2
20.2
73
262
C03DA01
ATC
spironolactone; oral
5.5
15.6
40
103
JJ1LE
NOMESCO Finland
Ultrasound elastography of liver
53.1
15.6
18
*
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
85.6
13.9
15
*
R18
ICD-10 Finland
Ascites
22.6
13.5
19
10
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.6
11.4
25
55
K76.9
ICD-10 Finland
Liver disease, unspecified
31.7
11.0
14
5
K73.2
ICD-10 Finland
Chronic active hepatitis, not elsewhere classified
121.0
10.6
11
*
C03CA01
ATC
furosemide; systemic
3.6
10.1
66
320
L04AX01
ATC
azathioprine; systemic
13.1
10.0
17
15
A07EA06
ATC
budesonide; oral, local oral
11.7
10.0
18
18
I85.0
ICD-10 Finland
Oesophageal varices with bleeding
60.4
9.8
11
*
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
15.8
9.0
14
10
TJJ00
NOMESCO Finland
Percutaneous needle biopsy of liver
97.1
8.5
9
*
K75.4
ICD-10 Finland
Autoimmune hepatitis
+∞
8.4
8
*
JCA22
NOMESCO Finland
Endoscopic ligature of oesophageal varices
36.3
8.2
10
*
D64.9
ICD-10 Finland
Anaemia, unspecified
3.8
8.0
29
94
K73.9
ICD-10 Finland
Chronic hepatitis, unspecified
48.5
7.8
9
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
13.2
7.8
13
11
ZX120
NOMESCO Finland
Intravenous
3.9
7.7
26
80
D97
ICPC
Liver disease NOS
85.6
7.5
8
*
K74.0
ICD-10 Finland
Hepatic fibrosis
85.6
7.5
8
*
L04AA06
ATC
mycophenolic acid; systemic
17.2
7.4
11
7
M05BA04
ATC
alendronic acid; oral
3.9
7.4
25
77
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
32.3
7.3
9
*
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
32.3
7.3
9
*
UJF32
NOMESCO Finland
Coloscopy
3.0
7.2
48
226
K83.0
ICD-10 Finland
Cholangitis
18.1
6.9
10
6
M34.1
ICD-10 Finland
CR(E)ST syndrome
42.7
6.8
8
*
L04AD02
ATC
tacrolimus; systemic
24.2
6.8
9
*
K92.1
ICD-10 Finland
Melaena
4.6
6.6
17
42
K75.9
ICD-10 Finland
Inflammatory liver disease, unspecified
19.4
6.4
9
5
JJC00
NOMESCO Finland
Allogenic transplantation of liver
28.5
6.3
8
*
A06AD11
ATC
lactulose; oral
3.2
6.3
31
121
A07AA11
ATC
rifaximin; oral
+∞
6.3
6
*
5716A
ICD-9 Finland
Chronic liver disease and cirrhosis, Biliary cirrhosis[CIRRHOSIS BILIARIS PRIMARIA]
+∞
6.3
6
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.9
6.3
38
167
C10AC01
ATC
colestyramine; oral
10.9
6.2
11
11
127
Kela drug reimbursment
Transplant complication
16.1
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
66
108
13.61
44.72
5.8
2.9
0.18
0.21
g/l
2.89
61
102
21
12
21.22
14.51
1.6
1.2
—
—
—
0
0
16
14
13.12
9.42
1.8
1.4
—
—
—
0
0
15
15
11.36
8.33
1.9
1.7
221.75
200.00
u/ml
—
8
7
92
606
4.03
7.77
14.6
3.4
131.18
51.42
u/l
5.15
92
565
10
5
21.76
7.27
7.3
7.0
79.30
104.20
%
—
10
5
88
580
3.50
7.07
14.6
7.3
1.20
1.21
mmol/l
0.72
73
493
56
291
2.87
6.91
3.8
2.3
5.38
3.01
mg/l
1.42
50
255
17
42
4.60
6.63
2.2
1.7
1.82
6.55
iu/ml
—
6
8
13
17
8.50
6.33
1.8
1.4
164.88
152.87
au/ml
—
5
6
16
31
5.85
5.98
1.8
1.5
—
—
—
0
0
87
598
3.10
5.93
14.3
10.2
4.26
4.20
e9/l
0.04
80
512
39
180
2.80
5.85
1.9
2.0
—
—
—
0
0
80
534
2.78
5.62
13.8
6.4
1.20
1.21
mmol/l
0.97
73
491
42
208
2.64
5.44
9.3
3.3
0.79
0.82
mmol/l
1.09
42
198
31
134
2.82
5.20
1.9
2.0
—
—
—
0
0
30
128
2.84
5.15
2.0
2.0
—
—
—
0
0
21
78
3.09
4.56
3.2
1.7
—
—
—
0
0
9
14
6.89
4.07
1.1
1.3
—
—
—
0
0
12
29
4.51
3.84
1.3
1.7
—
—
—
0
0
30
148
2.41
3.76
7.6
6.8
-1.03
1.10
mmol/l
1.62
22
130
12
30
4.35
3.72
1.2
1.2
—
—
—
0
0
69
485
2.12
3.54
6.1
2.8
—
—
estimate
—
0
0
29
147
2.32
3.40
3.9
4.9
2.97
55.78
ug/l
0.60
24
122
6
7
8.97
3.30
1.0
1.0
—
—
—
0
0
43
259
2.08
3.29
3.9
2.4
—
—
—
0
0
25
121
2.38
3.24
8.4
4.0
5.30
5.68
kpa
1.24
25
116
32
177
2.14
3.02
7.9
6.3
105.72
104.16
mmol/l
0.94
32
177
10
28
3.82
2.86
1.3
1.1
—
—
—
0
0
8
18
4.70
2.85
1.0
1.4
—
—
—
0
0
9
23
4.16
2.84
1.1
1.4
—
—
—
0
0
8
22
3.83
2.41
2.6
1.4
—
—
—
0
0
5
8
6.48
2.39
2.2
1.6
—
—
—
0
0
57
411
1.80
2.37
4.3
3.6
2.32
2.36
mmol/l
0.97
52
368
10
35
3.04
2.27
1.1
1.4
—
—
—
0
0
37
237
1.84
2.25
1.6
1.2
1.76
1.35
u/ml
0.15
11
61
5
9
5.75
2.23
1.2
1.2
—
—
—
0
0
5
9
5.75
2.23
1.2
2.6
—
—
—
0
0
43
291
1.78
2.17
3.9
2.8
361.97
340.34
umol/l
0.51
37
248
14
63
2.40
2.11
2.2
2.1
—
—
—
0
0
34
217
1.82
2.07
2.3
1.7
1191.62
1213.10
nmol/l
0.05
26
160
61
463
1.70
2.01
4.8
4.3
63.12
36.77
ng/l
0.34
53
355
9
33
2.88
1.98
1.1
1.4
—
—
—
0
0
16
79
2.20
1.97
4.0
3.1
258.75
237.64
ng/l
0.09
16
74
5
12
4.31
1.84
1.4
1.3
—
—
—
0
0
5
13
3.97
1.73
1.0
1.3
—
—
—
0
0
14
72
2.08
1.57
6.6
4.3
4.47
4.98
kpa
1.43
14
72
49
369
1.59
1.56
2.1
1.7
16.98
20.63
nmol/l
0.95
44
295
12
58
2.20
1.56
6.7
4.6
1.06
1.99
mmol/l
—
7
43
30
200
1.69
1.54
4.2
3.1
0.88
1.01
e6/l
0.12
15
105
45
333
1.59
1.54
5.8
3.4
0.55
0.45
e6/l
0.16
35
250
28
184
1.70
1.51
4.2
3.3
1.83
3.15
e6/l
0.50
12
90
21
127
1.81
1.50
5.9
4.2
—
—
—
0
0
7
28
2.60
1.48
1.3
1.6
—
—
—
0
0
5
16
3.22
1.45
1.0
1.1
—
—
—
0
0
13
67
2.07
1.45
3.2
2.3
1.12
1.31
%
0.39
13
67
44
330
1.55
1.40
5.4
4.5
0.00
0.02
estimate
0.50
16
123
16
93
1.84
1.29
21.7
6.4
22.98
24.59
mmol/l
0.93
16
93
6
25
2.48
1.26
1.7
1.3
—
—
—
0
0
50
395
1.48
1.21
6.1
3.5
—
—
—
0
0
9
45
2.09
1.08
4.0
2.2
—
—
—
0
0
60
505
1.41
0.98
2.5
2.2
91.81
97.02
pmol/l
0.33
35
230
33
252
1.44
0.92
2.1
3.2
2.51
2.47
mmol/l
0.62
25
226
66
569
1.39
0.92
5.9
4.4
0.00
0.00
estimate
-0.00
18
130
8
43
1.93
0.89
1.4
1.2
—
—
—
0
0
65
564
1.37
0.84
5.8
4.4
0.00
0.00
estimate
-0.00
16
124
6
32
1.92
0.83
3.7
1.6
—
—
—
0
0
66
576
1.36
0.81
6.2
4.4
0.00
0.00
estimate
-0.00
17
115
6
34
1.81
0.77
1.5
1.9
—
—
—
0
0
5
23
2.23
0.77
1.0
1.3
—
—
—
0
0
5
24
2.13
0.75
1.0
1.3
—
—
—
0
0
7
40
1.80
0.73
4.3
2.4
21.73
24.24
mmol/l
—
7
40
5
26
1.97
0.71
1.0
1.3
—
—
—
0
0
43
359
1.32
0.68
5.5
4.2
7.81
6.77
mg/mmol
0.15
30
214
5
28
1.82
0.67
3.0
1.4
0.68
0.86
g/l
—
5
28
5
30
1.70
0.62
1.0
1.3
—
—
—
0
0
6
36
1.70
0.57
1.5
2.1
—
—
—
0
0
10
67
1.54
0.51
4.3
2.3
0.76
0.63
%
—
10
67
56
499
1.25
0.50
2.9
2.7
—
—
—
0
0
83
774
1.29
0.50
60.3
24.5
15.27
13.87
%
7.69
83
767
30
249
1.28
0.49
2.5
2.0
427.08
474.95
pmol/l
0.61
25
203
5
32
1.59
0.43
1.8
1.3
221.60
89.79
pmol/l
—
5
32
97
929
1.35
0.42
41.2
19.4
71.90
75.15
ml/min/173m2
0.80
89
876
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
4.8
—
86.10
—
0
17
16
128
1.29
0.34
1.6
1.6
—
—
—
0
0
7
55
1.29
0.30
1.1
1.2
—
154.75
—
0
17
91
942
0.81
0.30
6.1
5.6
6.28
6.01
mmol/l
0.93
83
850
15
124
1.24
0.25
1.1
1.3
—
—
—
0
0
10
125
0.78
0.24
12.8
6.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
3.00
—
0
5
0
13
0.00
0.21
0.0
1.7
—
219.00
—
0
13
19
213
0.87
0.16
3.7
5.2
29.06
22.95
%
—
7
115
91
931
0.87
0.15
8.7
7.1
41.40
40.14
mmol/mol
0.45
86
862
27
250
1.11
0.12
6.7
4.3
1.02
1.02
kg/l
0.23
21
165
45
431
1.07
0.10
5.7
4.4
0.00
0.03
estimate
0.50
15
109
34
322
1.08
0.10
4.9
4.1
0.00
0.00
estimate
-0.00
14
105
6
54
1.12
0.09
1.8
1.7
—
—
—
0
0
95
961
0.92
0.05
6.3
6.5
2.27
2.62
mmol/l
3.77
89
870
92
909
1.07
0.05
5.5
5.7
2.28
1.94
mu/l
0.56
86
816
44
428
1.05
0.04
1.9
2.0
1.39
1.27
mmol/l
0.47
37
349
75
749
1.00
0.00
4.8
4.6
15.19
15.01
pmol/l
0.21
68
669
90
895
1.03
0.00
5.0
4.7
1.28
1.24
mmol/l
0.25
82
796
94
941
0.99
0.00
5.6
5.5
1.39
1.51
mmol/l
1.79
87
846
94
941
0.99
0.00
5.8
5.6
4.13
4.57
mmol/l
3.66
87
851
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.8
—
200.40
—
0
5
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
22.80
—
0
5
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
71.67
—
0
6
5
51
0.98
-0.00
1.8
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
6
61
0.98
-0.00
2.2
1.3
—
—
—
0
0
9
93
0.96
-0.00
1.9
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CHIRBIL_NAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHIRBIL_NAS | 4.689 [3.16, 6.97] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.134 |
During the follow-up period (1.1.1998 — 31.12.2019), 149 out of 349 females with CHIRBIL_NAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHIRBIL_NAS | 5.621 [3.23, 9.79] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.01 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 207 males with CHIRBIL_NAS died.
Mortality risk
Mortality risk for people of age
years, who have CHIRBIL_NAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.314% | 1.206% |
| 5 | 2.226% | 6.182% |
| 10 | 6.182% | 15.232% |
| 15 | 11.143% | 27.835% |
| 20 | 19.285% | 44.691% |
Relationships between endpoints
↥Index endpoint: CHIRBIL_NAS – Biliary cirrhosis, NAS
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data